Small molecule inhibitors of the transmembrane receptor tyrosine kinase Axl as potential anti-cancer therapeutics
Year: 2009
Session type: Poster / e-Poster / Silent Theatre session
1Cancer Research Technology Discovery Lab, London, UK, 2Barts and London School of Medicine and Dentistry, Queen Mary, University of London, UK, 3Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, UK
Abstract
Following stimulation by its endogenous ligand Gas6, the transmembrane receptor tyrosine kinase (RTK) Axl mediates oncogenic transformation through its intracellular kinase domain (ICD).